Avatrombopag
Chemical compound / From Wikipedia, the free encyclopedia
Avatrombopag, sold under the brand name Doptelet, is a medication that used for certain conditions that lead to thrombocytopenia (low platelets) such as thrombocytopenia associated with chronic liver disease in adults who are to undergo a planned medical or dental procedure.[8][9] It was approved for medical use in the United States in May 2018,[10][11] the European Union in June 2019,[7] and Australia in January 2023.[1]
Quick Facts Clinical data, Pronunciation ...
Clinical data | |
---|---|
Pronunciation | a" va trom' boe pag |
Trade names | Doptelet |
AHFS/Drugs.com | Monograph |
MedlinePlus | a618032 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C29H34Cl2N6O3S2 |
Molar mass | 649.65 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) |
Close
It acts as a thrombopoietin receptor agonist.[12]